JP2009515901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515901A5 JP2009515901A5 JP2008540275A JP2008540275A JP2009515901A5 JP 2009515901 A5 JP2009515901 A5 JP 2009515901A5 JP 2008540275 A JP2008540275 A JP 2008540275A JP 2008540275 A JP2008540275 A JP 2008540275A JP 2009515901 A5 JP2009515901 A5 JP 2009515901A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- treatment
- inhibitor
- patient
- inhibitor according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- BUROJSBIWGDYCN-GAUTUEMISA-N Deforolimus Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- HKVAMNSJSFKALM-WDSGEKFTSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-WDSGEKFTSA-N 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 210000002307 Prostate Anatomy 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960001302 ridaforolimus Drugs 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (11)
- ｍＴＯＲ阻害剤を要治療患者に週に４日または５日連続してそれぞれの日に投与するがん治療に使用するためのｍＴＯＲ阻害剤。
- シロリムス、テムシロリムス、エベロリムスまたはＡＰ２３５７３である、請求項１に記載の阻害剤。
- その合計１日量が２〜８０ｍｇである、請求項１または２に記載の阻害剤。
- その投与が１日に２回以上に分けられるためのものである、請求項１〜３のいずれか１項に記載の阻害剤。
- 経口で投与されるためのものである、請求項１〜４のいずれか１項に記載の阻害剤。
- 前記使用が、追加の２〜３００ｍｇのｍＴＯＲ阻害剤を週に１回投与することをさらに含む、請求項１〜５のいずれか１項に記載の阻害剤。
- 前記使用が、該ｍＴＯＲ阻害剤に加えて、１または２以上の他の薬剤の投与をさらに含む、請求項１〜６のいずれか１項に記載の阻害剤。
- 患者ががん患者である、請求項１〜７のいずれか１項に記載の阻害剤。
- がんが、肉腫、リンパ腫、もしくは白血病、または膀胱がん、大腸がん、脳腫瘍、乳がん、頭部および頸部のがん、子宮内膜がん、肺がん、卵巣がん、膵臓がんもしくは前立腺がんである、請求項８記載の阻害剤。
- 治療が該薬剤を要治療患者に週に４日または５日連続してそれぞれの日に投与することを含むがん治療用薬剤を製造するためのｍＴＯＲ阻害剤の使用。
- 薬剤組成物を要治療患者に週に４日または５日連続してそれぞれの日に投与するｍＴＯＲ阻害剤による治療を受ける患者に投与するための形態の、ｍＴＯＲ阻害剤を含有する薬剤組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73676305P | 2005-11-14 | 2005-11-14 | |
| US60/736,763 | 2005-11-14 | ||
| PCT/US2006/044146 WO2007059106A2 (en) | 2005-11-14 | 2006-11-14 | Administration of mntor inhibitor to treat patients with cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013191029A Division JP2014012721A (ja) | 2005-11-14 | 2013-09-13 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515901A JP2009515901A (ja) | 2009-04-16 |
| JP2009515901A5 true JP2009515901A5 (ja) | 2010-01-21 |
| JP5709354B2 JP5709354B2 (ja) | 2015-04-30 |
Family
ID=38049229
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008540275A Expired - Fee Related JP5709354B2 (ja) | 2005-11-14 | 2006-11-14 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
| JP2013191029A Pending JP2014012721A (ja) | 2005-11-14 | 2013-09-13 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013191029A Pending JP2014012721A (ja) | 2005-11-14 | 2013-09-13 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070185150A1 (ja) |
| EP (2) | EP2662082A1 (ja) |
| JP (2) | JP5709354B2 (ja) |
| CN (2) | CN101360495B (ja) |
| AU (1) | AU2006315512B2 (ja) |
| CA (1) | CA2629714A1 (ja) |
| EA (1) | EA015922B1 (ja) |
| IL (1) | IL191356A0 (ja) |
| WO (1) | WO2007059106A2 (ja) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100266590A1 (en) * | 2006-08-02 | 2010-10-21 | Demetri George D | Combination therapy |
| CA2669415A1 (en) * | 2006-11-14 | 2008-05-22 | Ariad Pharmaceuticals, Inc. | Solid dosage form comprising ap23573 |
| WO2009117669A2 (en) | 2008-03-21 | 2009-09-24 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| PT2365802T (pt) * | 2008-11-11 | 2017-11-14 | Univ Texas | Microcápsulas de rapamicina e utilização para o tratamento de cancro |
| CN102481361B (zh) | 2009-04-16 | 2014-10-22 | 默沙东公司 | 用于治疗癌症的组合物和方法 |
| US8911766B2 (en) * | 2009-06-26 | 2014-12-16 | Abbott Cardiovascular Systems Inc. | Drug delivery compositions including nanoshells for triggered drug release |
| US10485792B2 (en) | 2009-08-26 | 2019-11-26 | Hadasit Medical Research Services & Development Limited | Sustained release delivery systems for the prevention and treatment of head and neck cancers |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| AU2011240735B2 (en) * | 2010-04-13 | 2015-01-29 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer |
| JP2012061053A (ja) | 2010-09-14 | 2012-03-29 | Yuuki Kitaoka | 投薬装置、投薬装置の作動方法及び投薬方法 |
| AR083267A1 (es) * | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
| BR112013027486A2 (pt) * | 2011-04-25 | 2017-02-14 | Novartis Ag | combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor |
| CA3125862A1 (en) * | 2011-12-02 | 2013-06-06 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| KR20150009540A (ko) * | 2012-05-16 | 2015-01-26 | 노파르티스 아게 | Pi-3 키나제 억제제에 대한 투여 요법 |
| EP2919759A4 (en) | 2012-11-14 | 2016-07-20 | Ohio State Innovation Foundation | MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES |
| US20160030401A1 (en) | 2013-03-13 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of intestinal polyp growth and cancer |
| CN104721158B (zh) * | 2013-12-24 | 2018-01-30 | 正大天晴药业集团股份有限公司 | 一种稳定的依维莫司片剂 |
| EP3089737B1 (en) | 2013-12-31 | 2021-11-03 | Rapamycin Holdings, LLC | Oral rapamycin nanoparticle preparations and use |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| CN106166296A (zh) * | 2016-07-01 | 2016-11-30 | 江南大学 | 一种辅助雷帕霉素治疗多种肿瘤的药物组合物 |
| CN107714719A (zh) * | 2017-11-08 | 2018-02-23 | 上海市第妇婴保健院 | 雷帕霉素在制备治疗白细胞介素‑27低表达子宫内膜癌的药物中的应用 |
| CN114767867A (zh) * | 2021-12-22 | 2022-07-22 | 中山大学孙逸仙纪念医院 | 一种用于治疗cdk4/6抑制剂耐药后的乳腺癌的药物组合物及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
| US5078999A (en) | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| US5321009A (en) | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
| DE69209183T2 (de) | 1991-06-18 | 1996-08-08 | American Home Prod | Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen |
| ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
| ES2176245T3 (es) | 1993-04-23 | 2002-12-01 | Wyeth Corp | Anticuerpos de ramapicinas de ciclo abierto. |
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| SI0649651T1 (en) | 1993-09-28 | 2001-02-28 | Scherer Gmbh R P | Soft gelatin capsule manufacture |
| US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
| US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| GB0000482D0 (en) | 2000-01-11 | 2000-03-01 | Norton Healthcare Ltd | Enteric coated pharmaceutical formulation |
| PT2269603E (pt) | 2001-02-19 | 2015-09-09 | Novartis Ag | Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano |
| DE60228699D1 (de) * | 2001-04-06 | 2008-10-16 | Wyeth Corp | Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil |
| BR0210112A (pt) | 2001-05-30 | 2004-06-08 | Novartis Ag | Derivados do ácido 2-{[n-(2-amino-3-(heteroarila ou arila)propionil)-aminoacil]-amino}-alquilborÈnico |
| US20030220297A1 (en) | 2002-02-01 | 2003-11-27 | Berstein David L. | Phosphorus-containing compounds and uses thereof |
| CN100415233C (zh) | 2002-09-17 | 2008-09-03 | 惠氏公司 | 口服制剂 |
| RU2328287C2 (ru) * | 2003-08-18 | 2008-07-10 | Пфайзер Продактс Инк. | Схема приема erbb2 противоопухолевых агентов |
| GB0327840D0 (en) * | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| WO2005070393A2 (en) | 2004-01-08 | 2005-08-04 | Wyeth | Directly compressible pharmaceutical composition of the rapamycin ester cci-779 |
| US7405497B2 (en) | 2004-04-13 | 2008-07-29 | Electrovaya Inc. | Integrated power supply system |
| MX2007003790A (es) * | 2004-09-30 | 2007-05-24 | Ariad Gene Therapeutics Inc | Metodo de tratamiento. |
| BRPI0607198A2 (pt) * | 2005-02-15 | 2016-11-01 | Wyeth Corp | composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica |
| GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| DE102005017313A1 (de) | 2005-04-14 | 2006-10-19 | Volkswagen Ag | Verfahren zur Darstellung von Informationen in einem Verkehrsmittel und Kombiinstrument für ein Kraftfahrzeug |
| AR058505A1 (es) * | 2005-11-04 | 2008-02-06 | Wyeth Corp | Combinaciones antineoplasicas de temsirolimus y malato de sunitinib |
-
2006
- 2006-11-14 AU AU2006315512A patent/AU2006315512B2/en not_active Ceased
- 2006-11-14 WO PCT/US2006/044146 patent/WO2007059106A2/en active Application Filing
- 2006-11-14 EP EP13179744.1A patent/EP2662082A1/en not_active Withdrawn
- 2006-11-14 US US11/598,850 patent/US20070185150A1/en not_active Abandoned
- 2006-11-14 CA CA002629714A patent/CA2629714A1/en not_active Abandoned
- 2006-11-14 CN CN2006800510347A patent/CN101360495B/zh not_active Expired - Fee Related
- 2006-11-14 JP JP2008540275A patent/JP5709354B2/ja not_active Expired - Fee Related
- 2006-11-14 EP EP06844354A patent/EP1962839A4/en not_active Withdrawn
- 2006-11-14 EA EA200801309A patent/EA015922B1/ru not_active IP Right Cessation
- 2006-11-14 CN CN2012100014166A patent/CN102579467A/zh active Pending
-
2008
- 2008-05-12 IL IL191356A patent/IL191356A0/en unknown
-
2013
- 2013-09-13 JP JP2013191029A patent/JP2014012721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515901A5 (ja) | ||
| JP2009539769A5 (ja) | ||
| IL273765A (en) | Combinations and forms of administration of therapeutic agents and combined treatment | |
| JP2014040437A5 (ja) | ||
| JP2008530248A5 (ja) | ||
| JP2009545601A5 (ja) | ||
| JP2011079858A5 (ja) | ||
| JP2009506054A5 (ja) | ||
| JP2008517991A5 (ja) | ||
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| JP2013518124A5 (ja) | ||
| JP2009536956A5 (ja) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP2015527374A5 (ja) | ||
| JP2005530735A5 (ja) | ||
| JP2011500589A5 (ja) | ||
| JP2015510945A5 (ja) | ||
| JP2011500650A5 (ja) | ||
| MA31227B1 (fr) | Composition pharmaceutique renfermant du phloroglucinol et du paracetamol. | |
| RU2009116629A (ru) | Азитромицин для лечения узелковых угрей | |
| JP2007538066A5 (ja) | ||
| Kalavrezos et al. | Mouth cancer for clinicians part 12: cancer treatment (chemotherapy and targeted therapy) | |
| Ramalakshmi et al. | A study on prescribing trends of supportive care drugs used in cancer chemotherapy in a tertiary care teaching hospital | |
| JP2010519274A5 (ja) |